NCT06680817

A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)

Real-World, Long-Term Data Collection to Gain Clinical Insights Into Faricimab (FaReal Study)

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 850 (estimated)
• Sponsor: Hoffmann-La Roche · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The FaReal study aims to evaluate the effectiveness, safety, clinical insights and treatment patterns in patients treated with faricimab, in neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) in at least one eye, in real-world routine clinical practice over a 2-year patient follow-up period. Additionally, the FaReal study also aims to describe and evaluate health economic aspects of previous anti-VEGF treatments and current treatment with faricimab.

Conditions

• Neovascular Age-related Macular Degeneration
• Diabetic Macular Edema

Interventions

Type	Name	Description
DRUG	Faricimab	Faricimab will be administered as per local clinical practice and local labeling.

Timeline

• Start date: 2025-02-05
• Primary completion: 2027-06-30
• Completion: 2028-06-30
• First posted: 2024-11-08
• Last updated: 2026-04-13

Locations

59 sites across 15 countries: Austria, Bulgaria, Czechia, Finland, Greece, Hungary, Ireland, Israel, Latvia, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia